SIRT2 and SIRT3 decrease invasiveness of hepatic cell carcinoma (HCC) (Kim H. S. et al., 2011; Zhang B. et al., 2013; Zeng et al., 2017; Chen et al., 2019), while SIRT1, SIRT5, and SIRT7 may act as cytoprotective agents for HCC cells, so the therapeutic strategy in such case is their inhibition, not activation (Kim et al., 2013; Chang et al., 2018; Farcas et al., 2019; Wei et al., 2019; Zhao et al., 2019). Here, SIRT2 is linked to hepatocellular carcinoma.